Small‐molecule targeting of inflammasome‐driven disease, while not currently clinically available, presents some advantages over the current use of targeted IL‐1β biologics such as anakinra, riloncept and canakinumab, which have been associated with the development of autoantibodies and increased risk of infections.55, 56. Here, IL1B is linked to infection.